Cashu Logo
HomeWatchlistNewsSignalsPicks
DJI
-1.23%
SPX
-1.60%
IXIC
-2.24%
FTSE
-0.70%
N225
-0.66%
AXJO
-0.92%
Cashu Logo
Log In
HomeWatchlistNewsSignalsPicks
Join our newsletter to keep up to date with us!
Cashu Logo Alt
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.

Company

  • About Us
  • Careers
  • Blog
  • News

Help & Support

  • Help Center
  • Contact Us
  • Pro Support

Legal

  • Privacy Policy
  • Terms of Use
InstagramYouTube

© 2024 Cashu PTY LTD.

Carpenter Technology: Manipal Hospital's Breakthrough in Cancer Treatment with CRS and HIPEC

publisher logo
Cashu
2 days ago
Cashu TLDR
  • Manipal Hospital Dhakuria successfully performed its first Cytoreductive Surgery with HIPEC, marking a milestone in cancer treatment.
  • The innovative procedure enhances treatment efficacy for complex gynecological and gastrointestinal cancers through combined surgery and localized chemotherapy.
  • Successful patient recovery highlights Manipal's commitment to advanced cancer care and its role in the Indian healthcare sector.
crs Logo
CRS
Carpenter Technology
3.38%

Innovative Cancer Treatment Marks a New Era at Manipal Hospital Dhakuria

In a groundbreaking development, Manipal Hospital Dhakuria in Kolkata successfully performs a 12-hour Cytoreductive Surgery (CRS) combined with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) on a 60-year-old woman diagnosed with advanced primary peritoneal carcinomatosis. This significant milestone not only highlights the hospital's commitment to advancing cancer care but also showcases the hospital’s capability to manage complex cases that require a multidisciplinary approach. The patient, initially misdiagnosed with chronic liver failure, faced severe breathing difficulties upon her arrival, necessitating immediate intensive care. After a comprehensive treatment plan involving drainage of lung fluid and a tailored chemotherapy regimen, she stabilizes and is transferred to a general ward, setting the stage for the innovative surgical procedure.

Dr. Ashutosh Daga, the Medical Oncologist overseeing the case, expresses pride in the hospital's first CRS with HIPEC, emphasizing the integration of various medical specialties essential for the procedure's success. CRS with HIPEC is particularly beneficial for patients suffering from select gynecological and gastrointestinal cancers, as it combines extensive surgical intervention with localized chemotherapy, enhancing treatment efficacy. The patient undergoes five months of chemotherapy, followed by optimal cytoreduction during surgery, where heated chemotherapy is administered directly to the abdominal cavity. This approach significantly boosts the likelihood of eradicating remaining cancer cells, leading to a positive treatment response and a remarkable recovery trajectory for the patient.

The patient’s discharge on the ninth day post-surgery in stable condition reflects the successful implementation of advanced cancer treatment protocols at Manipal Hospital Dhakuria. As a leading healthcare provider in India, Manipal Hospitals caters to over 7 million patients annually, bolstered by a network of 37 hospitals across 19 cities. With over 10,500 beds and a workforce exceeding 18,600 employees, the organization remains committed to delivering high-quality, affordable healthcare. Recent expansions, including the acquisition of Medica Synergie hospitals and AMRI Hospitals Limited, further enhance its service offerings, positioning it as a pivotal player in the evolving healthcare landscape.

The successful execution of this pioneering surgery not only reinforces Manipal Hospital's role in cancer treatment innovation but also signifies a broader commitment within the Indian healthcare sector to adopt advanced medical technologies and methodologies. This case serves as a beacon of hope for patients with complex cancer diagnoses, illustrating the potential for improved outcomes through cutting-edge medical interventions.

The content provided here is for informational purposes only and should not be considered financial or investment advice. Investing in stocks carries risks, including potential loss of principal. Always do your own research and consult with a licensed financial advisor before making any investment decisions. We are not responsible for any losses or damages resulting from your use of this information.

More News

Feature in Progress
This section is under development. Check back soon for updates!